Literature DB >> 33870422

Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.

Tobias Goschzik1, Anja Zur Muehlen1, Evelyn Doerner1, Andreas Waha1, Carsten Friedrich2, Peter Hau3, Torsten Pietsch1.   

Abstract

Adult medulloblastomas (MB) are rare. We investigated the genetic landscape and prognostic impact of genetic aberrations in a cohort of 117 adult medulloblastomas. Histological features and pathway activation were evaluated at the protein level; 14.5% showed wingless-type activation, 63.3% SHH activation, and 22.2% were classified as non-WNT/non-SHH-MB. Genome-wide copy number analysis was performed by molecular inversion probe array technology. MB-related genes were sequenced in WNT- and SHH-activated MBs. 79.7% of SHH-MBs showed desmoplastic/nodular histology; all other MBs had classic histology. WNT-MBs carried oncogenic CTNNB1 mutations in 88.2% and had monosomy 6 in 52.9%. In SHH-MBs, TERT promoter mutations occurred in 97%, mutations in PTCH1 in 38.2%, SMO in 15.5%, SUFU in 7.4%, and TP53-mutations in 4.1%. In all, 84.6% of non-WNT/non-SHH-MBs had an isochromosome 17q. A whole chromosomal aberration (WCA) signature was present in 45.1% of SHH-TP53-wild type (wt)-MBs and 65.4% of non-WNT/non-SHH-MBs. In 98 cases with survival data, WNT-MBs had a 5-year overall survival (OS) of 68.6%. SHH-MBs TP53wt type and non-WNT/non-SHH-MBs showed 5-year OS of 80.4% and 70.8%, respectively. TP53-mutant SHH-MBs represented a prognostically unfavorable entity; all patients died within 5 years. Patients with a WCA signature showed significantly increased OS (p = 0.011 for SHH-TP53wt-MBs and p = 0.048 for non-WNT/non-SHH-MBs).
© 2021 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Adults; Medulloblastoma; Mutations; Whole chromosomal aberrations

Mesh:

Year:  2021        PMID: 33870422     DOI: 10.1093/jnen/nlab020

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  3 in total

1.  Subgroup and subtype-specific outcomes in adult medulloblastoma.

Authors:  Paul A Northcott; Andrey Korshunov; Vijay Ramaswamy; Hallie Coltin; Lakshmikirupa Sundaresan; Kyle S Smith; Patryk Skowron; Luca Massimi; Charles G Eberhart; Karisa C Schreck; Nalin Gupta; William A Weiss; Daniela Tirapelli; Carlos Carlotti; Kay K W Li; Marina Ryzhova; Andrey Golanov; Olga Zheludkova; Oksana Absalyamova; Konstantin Okonechnikov; Damian Stichel; Andreas von Deimling; Caterina Giannini; Scott Raskin; Erwin G Van Meir; Jennifer A Chan; Daniel Fults; Lola B Chambless; Seung-Ki Kim; Alexandre Vasiljevic; Cecile Faure-Conter; Rajeev Vibhakar; Shin Jung; Sarah Leary; Jaume Mora; Roger E McLendon; Ian F Pollack; Peter Hauser; Wieslawa A Grajkowska; Joshua B Rubin; Marie-Lise C van Veelen; Pim J French; Johan M Kros; Linda M Liau; Stefan M Pfister; Marcel Kool; Noriyuki Kijima; Michael D Taylor; Roger J Packer
Journal:  Acta Neuropathol       Date:  2021-08-18       Impact factor: 15.887

2.  Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas.

Authors:  Tobias Goschzik; Martin Mynarek; Stefan Rutkowski; Torsten Pietsch; Evelyn Doerner; Alina Schenk; Isabel Spier; Monika Warmuth-Metz; Brigitte Bison; Denise Obrecht; Nina Struve; Rolf-Dieter Kortmann; Matthias Schmid; Stefan Aretz
Journal:  Acta Neuropathol       Date:  2022-10-01       Impact factor: 15.887

Review 3.  Adult Medulloblastoma: Updates on Current Management and Future Perspectives.

Authors:  Enrico Franceschi; Caterina Giannini; Julia Furtner; Kristian W Pajtler; Sofia Asioli; Raphael Guzman; Clemens Seidel; Lidia Gatto; Peter Hau
Journal:  Cancers (Basel)       Date:  2022-07-29       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.